Get the content you want anytime you want.
REGISTER NOW | SIGN IN

Select coverage from ASM Microbe 2017 Conference is included below:

Why is Multidrug-Resistant <i>Pseudomonas aeruginosa</i> a Priority Pathogen?
Jason Pogue, PharmD, BCPS-ID, Clinical Pharmacist, Infectious Diseases, Sinai-Grace Hospital, explains why Pseudomonas aeruginosa is one of the World Health Organization’s critical priority pathogens for new research and development priorities.
Prevalence of Confirmed Vs. Declared Beta-Lactam Allergies in Patients
Davey Legendre, PharmD, MBA, BCPS, sheds light on the prevalence of confirmed beta-lactam allergies in patients.
Cities Hold a Large Share of the Global HIV Burden
Benjamin Young, MD, PhD, shares how many catalysts for the HIV epidemic exist within cities.
In Which Patients is Cytomegalovirus Most Harmful?
Genovefa Papanicolaou, MD, explains in which patient population is CMV most harmful.
Examining the Surprisingly High Impact of Viruses on CAP and the Utility of Procalcitonin in Treatment Decisions
The impact of viruses on community-acquired pneumonia seems to be greater than initially realized and the use of procalcitonin may help distinguish infection type for appropriate treatment.
Is Oritavancin Still Effective When It Comes to Treating Skin Infections?
Contagion® sat down with Rodrigo Mendes, PhD, to discuss research exploring evolving resistance among antibiotics to treat skin infections.
What Are The Drawbacks Of Current Front-Line Drugs to Treat <i>C. difficile</i> Infection?
Kirk Hevener, PharmD, PhD, explains the drawbacks of first-line drugs that are currently used to treat C. difficile infections.
Data Presented at ASM Microbe 2017 Highlight Progress on New Antibiotics: Business Watch Report
The weekly Business Watch includes the latest industry news that practitioners working in infectious diseases need to know.
FEATURED
We break down our top HIV news stories of 2017. Did you read them all?
x